Researchers at the Icahn School of Medicine at Mount Sinai, the CUNY Graduate School of Public Health & Health Policy, and Weill Cornell Medicine are launching an innovative clinical trial that integrates nutrition directly into the treatment of metabolic liver disease. The program will provide medically tailored meals to patients with metabolic dysfunction-associated steatohepatitis (MASH) who are receiving new drug therapies, aiming to make behavioral lifestyle changes more achievable and sustainable.

Led by Drs. Xiaotao (Rony) Zhang, Meena Bansal, and Jeffrey Lazarus, the study represents a novel “food is medicine” approach that addresses both clinical and social determinants of health. By combining nutritional intervention with pharmacologic therapy, the trial seeks to improve outcomes, enhance treatment efficacy, and reduce health disparities related to diet and access to care.

Read more in the Specialty Report: https://mshs.co/4obq0Xv